Implant	age at time of surgery, gender	site of implant	seizure onset region	sMRI abnormality	location of surgery	pathology	outcome	follow up interval (months)
1	13F	R F,T	R T	R MTS	R ATL	HS	IA	14
2**	32M	L T,O	L T,O junction	L T cavmal, MTS	L Lat. T	CH	IVB	9
3†	33M	L T,O,MT	T, MT	L T cavmal, MTS	L Lat. T, A+H	HS	IVB	13
4	50M	BL T, R F	R MF	Rt. F encmal	R ATL+ inf F,	gliosis	IID	20
5	50F	L T,P,O,IH	L O	L O encmal	L T, O	no chronic findings	IIB	51
6	30F	R T,P,O,IH	R P	none	R P	CG	IIIA	65
7	45F	L T,O	L T	L encmal	L ATL	CG	IA	34
8	16M	R F,P,T,O	R T	none	R T	CG	IVB	78
9	33F	L T,O	L T	none	L ATL	CA1 gliosis	IA	55
10	20F	R P,T,O,I	R O, MT	none	R ATL+O	hippocampal gliosis	IA	54
11	10F	R O, IH	R MO	R MO piloastro	right focal O	pilocytic astrocytoma	IIB	73
12	44F	L F,T	L T	L F encmal	L ATL	CG	IVB	10
13	33F	R F,T,O	R T	R MF FCD	R ATL	CG	IA	23
14	18F	R T,P,O	R T,P,O junction	none	R T, P	normal	IA	74
15	29F	L F,T,P	L T,O	FCD, SEN	L T, O	CG	1A	48
16	25M	L F,T	L T	L T DNET	L T	DNET	III	30
17	13F	R F,T,P,O,I	R O	R encmal	R T, F, P(MST)	gliosis	IVB	63
18	15F	L F,T,IH	LMF	none	L MF	CG	IA	59
19	29M	R F,T,P	R F	R F DNET	R F	DNET	IV	17
20	60M	BL F, BL T	R IF	R F piloastro	R OF	pilo astro	IV	31
21	21M	R F,T,P,IH	R F	none	R F	microdysgenesis	ID	30
22	37M	R F,T,P,IH	R F	none	R F	CG	II	48

Implant	age at time of surgery, gender	site of implant	seizure onset region	sMRI abnormality	location of surgery	pathology	outcome	follow up interval (months)
23	33F	L F,T,P	L T	diffuse heterotopia	L ATL	CG	IIB	60
24	54M	R F,T,P	R T	none	L ATL	no chronic findings	IA	30
25	46F	R F,P,IH	R Ant. C	R P cav mal	R F,C	no tissue provided	IIB	14
26	17M	R T,P,O,IH	R post. C, P	FCD	R MF, post. C, P	FCD IIb	IIB	12
27	18F	R F,T,P,IH	R F,P	R encmal	R F,P	normal	IIB	41
28**	9F	R F,T,P	R F	none	R F	FCD, no balloon cells	IV	11
29	17M	R F,P BL IH	R F	nonspecific	R F	hyaline astrocytopathy	IA	24
30	41M	R F,T,P	R P	R P encmal	R T,P	CG	IB	46
31	34F	L T,F	L MT	nonspecific	L ATL	chronic vascular changes	IV	11
32	16F	R F,T,P	R F,T	R MTS	R F, T	normal	III	16
33	22M	L F,T	L MT	L MTS	L ATL	HS, CG	IA	12
34	20F	L P	L P	L P AVM	L P	CG	IA	47
35	47M	L F, R F, IH	L IH	parasagital meningioma	L C	no tissue provided	IA	13
36	32M	R F,P	R P	R P FCD	R P	FCD IIB	IA	30
37	34F	L F,T,P	L F	none	L F	FCD IIB	IA	28
38	36F	L F,P, IH	L, P,IH	none	L P, IH	normal	III	28
39	27M	L F,P	L F	L F FCD	L F	FCD IIB	IA	23
40	27M	R F,T,P,IH	L P, IH	none	L P, IH	FCD IIA	III	22
41	25F	R F,T,P,O	R T	none	R T	FCD IIB	IA	21
42	32M	L F,P	L F	L F FCD	L F	FCD IIB	IA	18
43	33F	R F,P	R P	R P FCD	R P	FCD IIB	IA	16
44	33F	R P,T,O	R P	R P DNET	R P	DNET	IA	13
45	39M	L P	L	L P cav mal	R P	CH	2D	12
46	20M	L F,T	L T	none	L T	CG	IA	19

Table e-1: Patient information for the study population. Outcomes are given according to Engel classification. Pathology findings related to acute effects of surgical electrode implantation, e.g. reactive gliosis, are not included. Pathology reports describing only acute changes are listed as "no chronic findings". Abbreviations include: L = left, R = right, B = bilateral, Post = posterior, F = frontal, T = temporal, P = parietal, O = occipital, M = mesial, IH = interhemispheric, I = insular, C = cingulate, MTS=mesial temporal sclerosis, ATL = anteromesial temporal lobectomy, HS = hippocampal sclerosis, EncMal=encephalomalacia, FCD = focal cortical dysplasia, SEN = subependymal nodular heterotopia, DNET = dysembryoplastic neuroepithelial tumor, AVM = arteriovenous malformation, CH = cavernous hemangioma, CavMal = cavernous malformation, CG = Chaslin's marginal gliosis. MST = multiple subpial transections. * lost to follow up, ** patient underwent another epilepsy surgery at the end of the follow-up period, ‡ implants #2 and #3 in the same patient.